Veracyte VCYT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $139.07M-1.1% | $140.64M+6.6% | $131.87M+1.3% | $130.16M+13.7% | $114.47M-3.5% | ||
| —— | —— | —— | —— | —— | ||
| $101.16M-0.8% | $101.97M+11.7% | $91.28M+1.7% | $89.77M+12.9% | $79.51M+1.0% | ||
| 72.7%+0.2pp | 72.5%+3.3pp | 69.2%+0.3pp | 69%-0.5pp | 69.5%+3.1pp | ||
| $27.1M+30.0% | $20.85M+30.5% | $15.98M-1.7% | $16.26M-8.2% | $17.72M-8.1% | ||
| $27.16M+4.7% | $25.94M+6.1% | $24.46M-3.4% | $25.32M+3.5% | $24.45M-1.5% | ||
| $23.68M+36.4% | $17.37M-36.3% | $27.28M-15.6% | $32.33M-4.4% | $33.81M+25.6% | ||
| —— | —— | —— | —— | —— | ||
| $78.51M+21.2% | $64.78M-5.2% | $68.34M-28.1% | $95.04M+24.1% | $76.6M+2.7% | ||
| $22.65M-39.1% | $37.2M+62.1% | $22.95M+536% | -$5.27M-281% | $2.9M-30.4% | ||
| 16.3%-10.2pp | 26.4%+9.0pp | 17.4%+21.4pp | -4%-6.6pp | 2.5%-1.0pp | ||
| $7.33M+113% | $3.44M+185% | -$4.06M-162% | $6.52M+44.1% | $4.52M— | ||
| $29.97M-26.2% | $40.63M+115% | $18.89M+1,411% | $1.25M-83.2% | $7.43M+116% | ||
| $1.27M— | —— | -$248K-111% | $2.23M+485% | $381K— | ||
| $28.71M-30.2% | $41.15M+115% | $19.14M+2,053% | -$980K-114% | $7.05M+37.8% | ||
| 20.6%-8.6pp | 29.3%+14.7pp | 14.5%+15.3pp | -0.8%-6.9pp | 6.2%+1.8pp | ||
| $0.35-30.0% | $0.50+108% | $0.24+2,500% | -$0.01-111% | $0.09+50.0% | ||
| $28.08M-33.9% | $42.49M+50.6% | $28.21M+12,666% | $221K-97.3% | $8.27M-20.7% | ||
| 20.2%-10.0pp | 30.2%+8.8pp | 21.4%+21.2pp | 0.2%-7.1pp | 7.2%-1.6pp | ||
| $22.65M-39.1% | $37.2M+62.1% | $22.95M+536% | -$5.27M-281% | $2.9M-30.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Veracyte's profit margins?
- Gross margin is 70.9% and operating margin is 14.3%, with a 16.2% net margin.
- Where does Veracyte's income statement data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.